Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease

Sacco, 1995, Race–ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study, Stroke, 26, 14, 10.1161/01.STR.26.1.14 Wong, 1998, Intracranial stenosis in Chinese patients with acute stroke, Neurology, 50, 812, 10.1212/WNL.50.3.812 Chimowitz, 2005, Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis, N Engl J Med, 352, 1305, 10.1056/NEJMoa043033 Arenillas, 2001, Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study, Stroke, 32, 2898, 10.1161/hs1201.099652 Arenillas, 2003, C-reactive protein predicts further ischemic events in first-ever TIA and stroke patients with intracraneal large-artery occlusive disease, Stroke, 34, 2463, 10.1161/01.STR.0000089920.93927.A7 Arenillas, 2008, Progresión of symptomatic intracraneal large-artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis, Stroke, 39, 1456, 10.1161/STROKEAHA.107.498600 Elkind, 2009, High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction, Stroke, 40, 3233, 10.1161/STROKEAHA.109.552802 Cederholm, 2004, Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus, Arthritis Rheum, 50, 2869, 10.1002/art.20432 Rosenson, 2009, Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease, Cardiovasc Drugs Ther, 23, 93, 10.1007/s10557-008-6148-1 Persson, 2008, Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden, Atherosclerosis, 200, 191, 10.1016/j.atherosclerosis.2007.12.001 Robins, 2008, Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial, Arterioscler Thromb Vasc Biol, 28, 1172, 10.1161/ATVBAHA.107.160739 Nambi, 2009, Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the atherosclerosis risk in communities (ARIC) study, Stroke, 40, 376, 10.1161/STROKEAHA.107.513259 Arenillas, 2004, High lipoproteína (a), diabetes and the extent of symptomatic intracranial atherosclerosis, Neurology, 63, 27, 10.1212/01.WNL.0000132637.30287.B4 Arenillas, 2009, C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses, Cerebrovasc Dis, 28, 95, 10.1159/000222660 Elkind, 2006, High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke, Arch Intern Med, 166, 2073, 10.1001/archinte.166.19.2073 Ballantyne, 2004, Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 109, 837, 10.1161/01.CIR.0000116763.91992.F1 Elkind, 2009, Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke, Cerebrovasc Dis, 27, 42, 10.1159/000172633 Wassertheil-Smoller, 2008, Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women, Hypertension, 51, 1115, 10.1161/HYPERTENSIONAHA.107.103721 Oei, 2005, Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study, Circulation, 111, 570, 10.1161/01.CIR.0000154553.12214.CD Furie, 2007, Lipoprotein-associated phospholipase A2 activity predicts early stroke recurrence [abstract], Stroke, 38, 458 Thompson, 2010, Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Lancet, 375, 1536, 10.1016/S0140-6736(10)60319-4 Virani, 2007, The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis, Curr Atheroscler Rep, 9, 97, 10.1007/s11883-007-0004-9 Persson, 2007, Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects, Arterioscler Thromb Vasc Biol, 27, 1411, 10.1161/ATVBAHA.107.142679 Cucchiara, 2009, Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA, Stroke, 40, 2332, 10.1161/STROKEAHA.109.553545 O’Donoghue, 2006, Circulation, 113, 1745, 10.1161/CIRCULATIONAHA.105.612630 Caslake, 2000, Lipoprotein-associated phospholipase A(2), plateletactivating factor acetylhydrolase: a potential new risk factor for coronary artery disease, Atherosclerosis, 150, 413, 10.1016/S0021-9150(99)00406-2 Cushman, 1999, Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study, Circulation, 100, 717, 10.1161/01.CIR.100.7.717 Kardys, 2006, Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study, Arterioscler Thromb Vasc Biol, 26, 631, 10.1161/01.ATV.0000201289.83256.cf Mannheim, 2008, Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques, Stroke, 39, 1448, 10.1161/STROKEAHA.107.503193 Cao, 2003, C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly. The cardiovascular health study, Circulation, 108, 166, 10.1161/01.CIR.0000079160.07364.6A